ArticlePhysiological research2026
Synergistic Cardiac Protection by Thymoquinone and Valproic Acid in Absence Epilepsy.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the effects of thymoquinone (T) and valproic acid (VPA), alone and in combination, on cardiomyocyte damage induced by absence epilepsy (AE) in rats. Adult male Wistar rats (C, T) and Genetic Absence Epilepsy Rats from Strasbourg (GAERS; AE, AE+T, AE+V, AE+V+T) were assigned to six experimental groups. C and AE received solvent; T and AE+T received thymoquinone (10 mg/kg, o.g.); AE+V received VPA (200 mg/kg, i.p.); AE+V+T received both treatments for 8 days. Hearts were collected for histological (Masson's trichrome) and biochemical analyses. AE caused molecular changes in cardiomyocytes without fibrosis, decreasing total antioxidant status (TAS) (-8.7 %) and increasing total oxidant status (TOS) (+50.7 %), oxidative stress index (OSI) (+155.5 %), MDA (+50.8 %), caspase-8 (+43.8 %), cleaved caspase-3 (+73.5 %), NF-?B (+239.4 %), TNF-? (+141.2 %), IL-6 (+12.9 %). Compared with the AE group, T increased TAS (+48.2 %), IL-6 (+5.8 %) and reduced OSI (-36.7 %), caspase-8 (-16.0 %), cleaved caspase-3 (-37.5 %), TNF-? (-1.8 %). VPA increased TAS (+58.5 %), while reducing TOS (-15.7 %), OSI (-48.9 %), MDA (-31.9 %), IL-6 (-14.1 %), caspase-8 (-27.3 %), cleaved caspase-3 (-51.0 %), TNF-alpha (-8.9 %), and NF-kappaB (-28.5 %). The VPA+T combination further improved these alterations, decreasing TOS (-24.8 %), OSI (-54.5 %), MDA (-35.6 %), TNF-alpha (-16.3 %), caspase-8 (-27.7 %), cleaved caspase-3 (-47.1 %), NF-kappaB (-31.8 %) and IL-6 (-26.9 %) while increasing TAS (+59.8 %). Our study demonstrates that AE increases oxidative stress, apoptosis and inflammation in cardiac tissue. While T and VPA alone showed limited protective effects, their combined administration significantly attenuated cardiac damage, supporting this approach as a promising strategy for cardiac protection.
Indexed as
Identifiers
42187503PMC13225446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.